COMMUNIQUÉS West-GlobeNewswire

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
16/06/2025
Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE [...]
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program
16/06/2025
Millar to Lead Financial Strategy as Syncromune Scales Development of the SYNC-T® Novel Immunotherapy Platform for Solid Tumor Cancers FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2025 (GLOBE NEWSWIRE) -- [...]
SS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company’s SSi Mantra 3 Surgical Robotic System
16/06/2025
Surgery performed by Dr. Juan Zuniga at Interhospital in Guayaquil, Ecuador FORT LAUDERDALE, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII [...]
Solera HALO™ Platform Adds Rapid Configurability Tool for Integrated Digital Health Networks
16/06/2025
Enhancements Enable the Onboarding of New Providers in Days – Streamlining Speed to Market and Reducing Costs for Employers and Health Plans PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- Solera Health , the premier digital [...]
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
16/06/2025
Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the [...]
Bon Natural Life Announces Distribution Agreement with Tianjin Merrill-Youli Trading Co., Ltd.
16/06/2025
XI’AN, China, June 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“Bon” or the “Company”), a leading bio-ingredient solutions provider for natural, health, and personal care industries, today [...]
3Daughters to Lead Panel at BIO International Convention on Patient Reported Outcomes that Includes FDA Division Director
16/06/2025
Dr. Christina Chang, FDA Director of the Division of Urology, Obstetrics and Gynecology to Join Panel Discussing Patient Reported Outcomes through the Lens of IUD Insertion Pain BOSTON, June 16, 2025 (GLOBE NEWSWIRE [...]
INVO Fertility’s Wisconsin Clinic Recognized on Newsweek’s List of America’s Best Fertility Clinics for 2025
16/06/2025
MIDDLETON, Wis. and SARASOTA, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced [...]
Psychemedics Releases 2025 Workforce Insights Report
16/06/2025
Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced [...]
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
16/06/2025
LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of [...]
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
16/06/2025
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the [...]
BlueGenes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience
16/06/2025
SCOTTSDALE, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- BlueGenes , a leading pharmacogenetics (PGX) solution, and Levrx Technology , a digital pharmacy engagement platform, have announced a strategic partnership. Together [...]
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
16/06/2025
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical [...]
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
16/06/2025
XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL for UK approval via MHRA’s International Recognition Procedure AVEROA [...]
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
16/06/2025
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein [...]
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
16/06/2025
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that [...]
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
15/06/2025
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such [...]
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
15/06/2025
EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude [...]
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
15/06/2025
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late- [...]

Pages